阿帕替尼联合替吉奥治疗晚期胃癌疗效分析

汪孟森

【摘 要】目的：对晚期胃癌患者接受阿帕替尼联合替吉奥治疗后的疗效进行观察分析，为临床提供参考。方法：选取2017年3月至2019年2月来我院进行诊疗的晚期胃癌患者46例作为研究对象，将其随机分为研究组与对照组，每组各23例。其中对照组给予替吉奥单药治疗，研究组给予阿帕替尼联合替吉奥治疗，对比治疗后两组的疗效及不良反应发生率。结果：研究组患者疾病控制率为73.91%，顯著高于对照组疾病控制率43.48%，差异显著，P<0.05;且研究组患者不良反应率为21.74%，与对照组比较差异不显著，P>0.05。结论：阿帕替尼联合替吉奥对晚期胃癌患者治疗具有明确应用价值。

【关键词】晚期胃癌;阿帕替尼;替吉奥;疗效

【中图分类号】R735.2 【文献标识码】B 【文章编号】1002-8714（2020）02-00-02

【Abstract】Objective： To observe and analyze the curative effect of patients with advanced gastric cancer after receiving apatinib combined with tegafur，. Methods： Forty-six patients with advanced gastric cancer who came to our hospital from March 2017 to February 2019 were enrolled in the study. They were randomly divided into study group and control group， with 23 cases in each group. The control group was treated with teggio monotherapy， and the study group was treated with apatinib and tegafur. The efficacy and adverse reaction rate of the two groups were compared. Results： The disease control rate of the study group was 73.91%， which was significantly higher than that of the control group （43.48%， the difference was significant， P<0.05）. The adverse reaction rate of the study group was 21.74%， which was not significantly different from the control group. 0.05. Conclusion： s Apatinib combined with tegafur has clear application value in the treatment of patients with advanced gastric cancer.

【Key words】advanced gastric cancer; apatinib; tiggio; efficacy

人体消化系统肿瘤中最为常见的是胃癌，且近些年来统计研究发现我国胃癌的患病人数越来越多[1]。作为一种消化道肿瘤，临床上，随着病情的不同，症状不同，初期常见症状为胃肠道反应，随着病情加重出现疼痛、体重降低等症状，与其他肿瘤一样，在临床上多采用放疗化疗治疗，但放疗化疗副作用较大，对患者身心产生较大不良影响，此病的发病原因尚不明确，关系比较密切的病因是日常饮食、亚硝酸盐摄入以及幽门螺旋杆菌感染等。胃癌在早期阶段表现并不明显，只有当恶性肿瘤侵及粘膜下层或胃壁全层时，症状才比较明显[2]。但进展至此时的胃癌已错过最佳的手术治疗时机。晚期胃癌患者对化疗的敏感性比较高，多采用全身化疗。研究发现阿帕替尼与替吉奥联合治疗对患者病情的改善具有明确疗效[3]。……